Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Celltrion Gains Foothold in Europe; Wins Clinical Trial Approval from Latvia For Herceptin Biosimilar

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Celltrion has secured an approval from EU member Latvia to perform clinical trials for its Herceptin (trastuzumab) biosimilar as part of its effort to prepare for the expiration of Roche's patent rights on the product in 2019 in Europe and the U.S

You may also be interested in...



Shocker For MNCs: India Steps Closer To Granting Compulsory Licenses On Herceptin, Sprycel, Ixempra

Buckling under pressure from domestic drug makers and patient groups, India readies to grant compulsory licenses for three key cancer drugs.

Shocker For MNCs: India Steps Closer To Granting Compulsory Licenses On Herceptin, Sprycel, Ixempra

Buckling under pressure from domestic drug makers and patient groups, India readies to grant compulsory licenses for three key cancer drugs.

Korean Government Shifts Attention To CRO Sector In Steady Drive To Build Up Biotech Infrastructure, Biosimilars

SEOUL - After realizing that it was a late comer, the Korean government is now moving to strengthen its local CRO industry to support a clinical trial infrastructure that is bursting at the seams as MNCs flock to Korea to conduct early-stage trials

Related Content

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel